We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

By LabMedica International staff writers
Posted on 02 Nov 2026

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. More...

Common sexually transmitted infections during pregnancy often cause no symptoms, making them difficult to identify through standard symptom-based care and leaving potentially treatable infections undetected. A new study highlights the potential value of broader detection, finding that repeated screening and treatment for these infections during pregnancy was associated with fewer preterm births.

Researchers at the University of Pennsylvania and the University of Southern California evaluated two approaches to screening and treating chlamydia, gonorrhea, and trichomoniasis during pregnancy. The first involved testing participants at their initial prenatal visit, treating detected infections, and performing a test-of-cure three weeks later for those treated. The second included screening and treatment at both the initial visit and between 30 and 34 weeks of pregnancy.

The randomized Philani Ndiphile Study enrolled 2,247 pregnant participants across four government health clinics in South Africa. Participants were assigned to first-visit screening and treatment, first-visit plus third-trimester screening and treatment, or standard symptom-based care. At baseline, approximately 27% tested positive for at least one of the three infections, and about 80% of infections caused no symptoms, highlighting the limitations of relying on symptoms alone.

Preterm birth occurred in 14.5% of participants screened twice, compared with 18.8% receiving standard care. In contrast, the rate in the one-time screening group was similar to that with standard care, at 18.9%. Repeat screening also identified infections later in pregnancy: 9.2% of participants tested in the third trimester were positive, including those with persistent, recurrent, or newly detected infections.

The twice-during-pregnancy approach did not significantly reduce the study’s primary combined outcome of preterm birth or low birth weight. It also did not reduce low birth weight when analyzed separately, and the authors cautioned that the preterm birth finding requires further study. The study was published in Clinical Infectious Diseases on October 27, 2026.

“Complications from preterm birth are among the leading causes of death among children under 5 years of age globally. This study suggests that testing for STIs during pregnancy could help us find and treat infections that might otherwise go unnoticed, and that screening more than once may be important for reducing the risk of preterm birth. Because most of the infections we found caused no symptoms, waiting for symptoms alone means we may miss an opportunity to intervene,” said Andrew Medina-Marino, Ph.D., adjunct associate professor of psychiatry at the University of Pennsylvania Perelman School of Medicine. 

“The results give us an important signal, but they don't settle the question of how often pregnant patients should be screened. The next step is understanding when screening can have the greatest impact and which patients are most likely to benefit,” said Medina-Marino.

Related Links
University of Pennsylvania 
University of Southern California


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The MIRAM GAGome Kit quantifies urine CS disaccharides by UHPLC-MS/MS, supporting exploratory and translational research across disease areas. (Photo courtesy of Elypta)

Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction

Cancer risk stratification in healthy adults often relies on established factors such as age and smoking history. However, several cancers highlighted in the study, including pancreatic, kidney, and brain... Read more

Molecular Diagnostics

view channel
Image: A blood test measuring circulating tumor DNA may help identify men with hormone-resistant oligoprogressive prostate cancer most likely to benefit from stereotactic body radiotherapy (Image Credit: Adobe Stock)

Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer

Advanced prostate cancer can progress despite hormone-based treatment, with imaging sometimes revealing only limited areas of active disease. For men with hormone-resistant oligoprogressive prostate cancer,... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.